In the pharmaceutical industry, Ursodeoxycholic Acid (UDCA) 150 mg is a naturally occurring, hydrophilic bile acid. As a pharmacist and manufacturer, I classify this as a hepatoprotective and cholelitholytic agent.
Unlike toxic bile acids that can damage liver cells, UDCA is “cytoprotective.” It works by displacing more harmful, hydrophobic bile acids from the gallbladder and liver, effectively acting as a chemical shield for the hepatobiliary system.
Primary Clinical Uses
-
Dissolution of Gallstones: Used to dissolve small-to-medium, radiolucent (non-calcified) cholesterol gallstones in patients who cannot undergo surgery.
-
Primary Biliary Cholangitis (PBC): The “gold standard” treatment for this autoimmune liver disease; it helps slow the progression of liver scarring (cirrhosis).
-
Cystic Fibrosis-Related Liver Disease: Often prescribed to improve bile flow in pediatric and adult patients with CF.
-
Prevention of Gallstones: Frequently used in patients undergoing rapid weight loss (such as after bariatric surgery) to prevent the formation of stones.
-
Chronic Hepatitis: Sometimes used as an adjunct therapy to improve liver enzyme profiles ($ALT$ and $AST$).
Mechanism of Action: The Three-Fold Protection
UDCA works through a combination of physical and chemical processes to protect the liver and gallbladder.
Cholesterol Desaturation: It reduces the secretion of cholesterol from the liver into the bile and inhibits the intestinal absorption of cholesterol. This makes the bile “under-saturated,” allowing existing cholesterol stones to gradually dissolve.
Bile Flow Stimulation (Choleretic Effect): It increases the volume of bile flow, helping to “flush” the bile ducts and reduce the concentration of toxic substances.
Cytoprotection: UDCA stabilizes the membranes of liver cells (hepatocytes) and protects them against the inflammatory damage caused by toxic bile salts that accumulate during cholestasis.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your WHO-GMP facility in Mumbai, Ursodeoxycholic Acid 150 mg is a high-value specialty asset:
-
The 150 mg vs. 300 mg Strength: While 300 mg is the standard adult therapeutic dose, the 150 mg tablet is essential for titration and for pediatric patients or those with milder symptoms. Offering this flexibility on your digital marketplace is a key B2B advantage.
-
Solubility Challenges: UDCA is a BCS Class II drug (low solubility, high permeability). In our manufacturing, we prioritize micronization and the use of specific surfactants to ensure the tablet meets strict BP/USP/IP dissolution standards.
-
Stability & Packaging: UDCA is relatively stable but sensitive to moisture. We utilize Alu-Alu blister packaging to ensure a 36-month shelf life, which is a major USP for export to Zone IVb regions.
-
Dossier Support: This is a high-growth “lifestyle and chronic care” molecule. We provide full CTD/eCTD Dossiers to support your firm in registering this as a premium generic against the innovator (Urso or Actigall).